Abalos Therapeutics GmbH

Abalos Therapeutics GmbH focuses on advancing innovative anti-cancer therapies using proprietary technologies that harness the immune system's response to combat tumors, aiming to improve treatment outcomes for cancer patients globally. Founded in 2019 in Germany, Abalos Therapeutics GmbH specializes in the development of anti-cancer therapies, particularly through its proprietary Adapt Innate technology. The company was founded by Karl Lang and is led by CEO Marcus Kostka. Abalos has engaged in two funding rounds, with the most recent being a Series A round on September 30, 2021, raising EUR 32.

5 million led by Seventure Partners. The total amount raised by the company is EUR 32. 5 million, with a current valuation of EUR 118. 835 million.

Abalos Therapeutics specializes in developing innovative anti-cancer therapies that leverage their proprietary Adapt Innate technology, focusing on harnessing the immunostimulatory properties of arenaviruses. Their lead product candidate, ABX-001, is designed to persist and replicate within cancerous and antigen-presenting cells, enabling a targeted immune response that combats primary tumors and their metastases. Abalos aims to initiate clinical trials for ABX-001 in 2025, with an overarching mission to create a diverse pipeline of therapeutics tailored for specific cancer indications. Abalos Therapeutics' revenue model is centered on partnerships and collaborations with healthcare institutions and research organizations.

Revenue is generated primarily through strategic alliances with pharmaceutical companies interested in bringing ABX-001 and future candidates to market. The company anticipates earning revenue through licensing agreements post-commercialization, incorporating upfront payments, milestone payments linked to clinical and regulatory successes, and royalties from product sales. Given its innovative mechanism of action, ABX-001 is positioned to command a premium in the oncology market. Abalos Therapeutics plans to utilize the EUR 32.

5 million raised in its Series A funding to advance ABX-001 into a Phase 1/2 trial targeting multiple solid tumors, while also expanding its pipeline. The company aims to initiate clinical trials for its lead product candidate in 2025, with a strategic focus on penetrating new markets, although specific regions for expansion have not been outlined. The recent funding will support the demonstration of early signs of clinical efficacy in expanded cohorts.